摘要
Non-steroidal anti-inflammatory drugs (NSAIDs) remain the principal pharmacological agents for symptom relief in patients with the rheumatic diseases. Host-guest chemistry, the basis of piroxicam β-cyklodekstrin (PBC) began to receive widespread attention following the award of the 1987 Nobel chemistry prize to Cram, Pederson and Lehn. β-cyklodekstrin is a soluble cyclic oligosaccharide that is able to modify the pharmacokinetics of various substances. The inclusion of piroxicam in β-cyklodekstrin increased the water solubility and rate of absorption of the drug without altering its clinical effects. Result of clinical trials shows that PBC is effective and well tolerated in the treatment of patients with acute and chronic pain. However when we use NSAIDs we should consider the clinical effects and potentially adverse events.
摘要译文
非甾体类抗炎药（NSAIDS）仍然是风湿病患者症状缓解的主要药理药物。宿主 - 阵线化学，Piroxicamβ-Cyklodekstrin（PBC）的基础后，在1987年诺贝尔化学奖授予Cram，Pederson和Lehn之后，开始受到广泛关注。β-Cyklodekstrin是一种可溶性的环状寡糖，能够修改各种物质的药代动力学。在β-Cyklodekstrin中纳入吡昔康，增加了药物吸收率，而不会改变其临床作用。临床试验的结果表明，PBC在急性和慢性疼痛患者的治疗中具有有效且耐受性。但是，当我们使用NSAID时，我们应该考虑临床效应和潜在的不良事件。
Jerzy Świerkot. Can non-steroidal anti-inflammatory drugs be improved?[J]. Reumatologia/Rheumatology, 2005,43(3)